Iovance Biotherapeutics, Inc.
IOVA
주식 순위
#2870
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
주가
$14.16
시가총액
$6.42B
변동 (1일)
4.00%
변동 (1년)
549.77%
국가
US
거래 Iovance Biotherapeutics, Inc. (IOVA)
카테고리
Healthcare
Iovance Biotherapeutics, Inc. (IOVA)의 EPS
June 2026 기준 EPS TTM: $-0.73
Iovance Biotherapeutics, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.73입니다. 2023년 말에는 회사의 EPS가 $-1.89였으며, 이는 2022년의 EPS $-2.49와 감소입니다.
Iovance Biotherapeutics, Inc.의 EPS 기록 (2008 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-0.73 | -42.97% |
| 2024 | $-1.28 | -32.28% |
| 2023 | $-1.89 | -24.10% |
| 2022 | $-2.49 | 11.66% |
| 2021 | $-2.23 | 18.62% |
| 2020 | $-1.88 | 25.33% |
| 2019 | $-1.50 | 18.11% |
| 2018 | $-1.27 | -9.93% |
| 2017 | $-1.41 | 46.88% |
| 2016 | $-0.96 | 54.84% |
| 2015 | $-0.62 | 29.17% |
| 2014 | $-0.48 | -81.54% |
| 2013 | $-2.60 | -37.20% |
| 2012 | $-4.14 | -87.77% |
| 2011 | $-33.84 | 1,275.61% |
| 2010 | $-2.46 | 14,370.59% |
| 2009 | $-0.02 | -63.91% |
| 2008 | $-0.05 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -2,472.60% |
US
|
|
| $-7.98 | 993.15% |
US
|
|
| $-5.29 | 624.66% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,900.00% |
NL
|
